A Markov Process Analysis Comparing the Cost Effectiveness of Maintenance Therapy with Citalopram versus Standard Therapy in Major Depression

PharmacoEconomics

Volumn 8, Issue 2, 1995, Pages 159-168

  Nuijten, Mark J C ^a   Hardens, Martin ^b   Souêtre, Eric ^c  

^a Benefit Research Group   (Netherlands)

^b Benefit Research Group   (France)

^c Benefit Research Group   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; CITALOPRAM; DOXEPIN; TRIMIPRAMINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DEPRESSION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

AMITRIPTYLINE; ANTIDEPRESSIVE AGENTS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; CITALOPRAM; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; DEPRESSIVE DISORDER; DOXEPIN; GERMANY; HUMANS; LONG-TERM CARE; MARKOV CHAINS; MODELS, ECONOMIC; RECURRENCE; TRIMIPRAMINE;

EID: 0029122093     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.2165/00019053-199508020-00007     Document Type: Article

References (49)

1. Depression: distress or disease? Some epidemiological considerations
2. The NIMH epidemiological catchment area program
3. Six-month prevalence of psychiatric disorders in three communities
4. The course of depressive psychoses
5. The epidemiology of depression
6. Follow-up of 53 bipolar manic-depressive patients
7. An 11-year follow-up of 110 depressed patients
8. The economic burden of depression
9. Relapse and recurrences in unipolar depression: short-term and long-term approaches
10. Adequacy and duration of antidepressant treatment in primary care
11. Pharmacotherapy of depressive disorders: a consensus statement
12. Paroxetine is better than placebo in relapse prevention and the prophylaxis of recurrent depression
13. A consensus development conference statement. Mood disorders: pharmacological prevention ofrecurrence
14. Efficacy of interpersonal psychotherapy as a maintenance treatment of recurrent depression: contributing factors
15. The course, morbidity and costs of depression
16. Continuation drug therapy for major depressive episodes: how long should it be maintained?
17. Studies on the course of recurrent endogenous affective disorders
18. Failure to demonstrate prophylactic efficacy of dothiepin
19. Five-year outcome for maintenance therapies in recurrent depression
20. Prophylactic lithium: double- blind discontinuation in manic-depressive and recurrent-depressive disorders
21. The prophylactic effect of f1uoxetine in unipolar depression
22. A 24-week study of 20mg citalopram, 40mg citalopram and placebo in the prevention of relapse of major depression
23. Measuring the economic costs of schizophrenia
24. Estimates of economic costs of alcohol and drug abuse and mental illness, 1985 and 1988
25. The cost of antidepressant drug therapy failure: a study of antidepressant use patterns in a medical population
26. The economic burden of depression
27. Arrêt de travail et depression: impact de la f1uoxetine
28. Methodological approaches to pharmacoeconomics
29. The economic costs of mental illness in Sweden 1975
30. The economic costs of schizophrenia
31. The economic costs of Alzheimer’s disease
32. Depression, disability days, and days lost from work in a prospective epidemiologic survey
33. The hidden mental health network
34. Detection of depressive disorder for patients receiving prepaid or fee-for-service care
35. Cost utility of maintenance treatment of recurrent depression with sertraline versus episodic treatment with dothiepin
36. The Markov process in medical diagnosis
37. What price depression? The cost of depression and the cost-effectiveness of pharmacological treatment
38. Citalopram and imipramine in the treatment of depressive patients in general practice: a Nordic multicentre clinical study
39. The financial implications of starting treatment with a selective serotonin reuptake inhibitor or tricyclic antidepressant in drug-naive depressed patients